Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Penumbra, Inc.    PEN

PENUMBRA, INC.

(PEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/10/2020 02/11/2020 02/12/2020 02/13/2020 02/14/2020 Date
183.22(c) 185.12(c) 185.51(c) 189.69(c) 190.44(c) Last
196 670 226 590 163 493 250 153 176 002 Volume
+3.90% +1.04% +0.21% +2.25% +0.40% Change
More quotes
Financials (USD)
Sales 2019 544 M
EBIT 2019 46,3 M
Net income 2019 38,9 M
Debt 2019 -
Yield 2019 -
Sales 2020 652 M
EBIT 2020 53,9 M
Net income 2020 47,8 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 176x
P/E ratio 2020 145x
Capi. / Sales2019 12,2x
Capi. / Sales2020 10,2x
Capitalization 6 649 M
More Financials
Company
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions... 
More about the company
Surperformance© ratings of Penumbra, Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on PENUMBRA, INC.
02/11PENUMBRA, INC. : Schedules Fourth Quarter and Full Year 2019 Earnings Release an..
PR
01/09PENUMBRA : Announces FDA Clearance of Indigo® Aspiration System for Treatment of..
BU
2019PENUMBRA, INC. : to Present at the 38th Annual J.P. Morgan Healthcare Conference
PR
2019PENUMBRA INC : Financial Statements and Exhibits (form 8-K)
AQ
2019PENUMBRA, INC. : Announces Investor Day 2019
PR
2019El Paso Walmart Reopening After Mass Shooting Amid Mixed Emotions
DJ
2019PENUMBRA : 3Q Earnings Snapshot
AQ
2019PENUMBRA INC : Results of Operations and Financial Condition (form 8-K)
AQ
2019PENUMBRA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
2019PENUMBRA, INC. : Reports Third Quarter 2019 Financial Results
PR
2019PENUMBRA : Indigo® Aspiration System IDE Trial for Acute Pulmonary Embolism Meet..
BU
2019WHAT'S NEWS : World-Wide -- WSJ
DJ
2019PENUMBRA, INC. : Schedules Third Quarter 2019 Earnings Release and Conference Ca..
PR
2019PENUMBRA : Announces First Patient Enrolled in Study of Mechanical Power Aspirat..
BU
2019PENUMBRA INC : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
More news
News in other languages on PENUMBRA, INC.
2019AVIS D'ANALYSTES DU JOUR : LVMH, Rémy Cointreau, Swisscom, Elior, Adidas, Peugeo..
More news
Sector news : Medical Equipment
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/13BAXTER INTERNATIONAL : Expects Restatement to Cut Income From Continuing Operati..
DJ
More sector news : Medical Equipment
Chart PENUMBRA, INC.
Duration : Period :
Penumbra, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PENUMBRA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 190,25  $
Last Close Price 190,44  $
Spread / Highest target 5,02%
Spread / Average Target -0,10%
Spread / Lowest Target -5,48%
EPS Revisions
Managers
NameTitle
Adam Elsesser Chairman & Chief Executive Officer
Sridhar Kosaraju President
Maggie S. Yuen Chief Financial Officer
David Barry Chief Technology Officer
Pankaj Tiwari Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
PENUMBRA, INC.15.93%6 649
ABBOTT LABORATORIES3.22%158 560
MASIMO CORPORATION16.14%9 841
NOVOCURE LIMITED10.55%9 220
ASAHI INTECC CO., LTD.-1.27%7 389
GETINGE-2.93%4 816